Linked Life Data

11035194

Source:http://linkedlifedata.com/resource/pubmed/id/11035194

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2000-11-28
pubmed:abstractText
Antisense oligonucleotides, ribozymes and DNAzymes have emerged as novel, highly selective inhibitors or modulators of gene expression. Indeed, their use in the treatment of diseases arising from genetic abnormalities has become a real possibility over the past few years. The first antisense drug molecule is now available for clinical use in Europe and USA. However, their successful application in the clinic will require improvements in cellular targeting and intracellular delivery. This review aims to look at recent advances in the in vitro and in vivo delivery of antisense oligodeoxynucleotides and ribozymes.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0169-409X
pubmed:author
pubmed:issnType
Print
pubmed:day
31
pubmed:volume
44
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3-21
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
The delivery of antisense therapeutics.
pubmed:affiliation
Aston Centre for Gene-based Therapeutics (ACGT), Pharmaceutical Sciences Research Institute, Aston University, Aston Triangle, B4 7ET, Birmingham, UK.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't